Nu Skin Enterprises Reports Record First-Quarter Results And Raises 2013 Guidance
"We kicked off the year with tremendous momentum, generating 22 percent local-currency revenue growth this quarter," said
Regional Results
EMEA. Revenue in the EMEA region was
Operational Performance
The company's operating margin was 15.0 percent for the quarter, compared to 15.5 percent in the prior year. The decrease in operating margin was primarily a result of planned brand-building efforts in
The company's income tax rate for the quarter was 34.4 percent compared to 36.5 percent in the prior-year period. The company's cash and short-term investment position at the end of the quarter was
Outlook
"Given the positive momentum of the business, we are on track to achieve another record year of revenue and earnings," said Hunt. "Our anti-aging product portfolio continues to drive strong consumer demand and impressive growth in our global sales force.
"The ageLOC product platform has become a game-changer for
"Given the strength of our business, as well as the optimism we have for the upcoming ageLOC weight management system, we are significantly raising our 2013 guidance," said
The company's management will host a webcast with the investment community on
About
Please Note: This press release, particularly the "Outlook" section, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, initiatives, strategies and new product introductions; statements of projections regarding revenue, operating margin, earnings per share, foreign currency impact and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
- any failure of current or planned initiatives or products to generate interest among distributors and customers and generate sponsoring and selling activities on a sustained basis;
- risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, including possible ingredient supply limitations;
- challenging economic conditions globally;
- risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- risks associated with general inquiries and complaints to consumer protection agencies in
Japan regarding the activities of some distributors; - regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
- continued regulatory scrutiny and investigations in Mainland China, which have from time to time in the past, and could in the future, negatively impact the company's business, including the interruption of sales activities in stores, loss of licenses, and the imposition of fines;
- adverse publicity related to the company's business, products, industry or any legal actions or complaints by distributors or others;
- any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of
the United States and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and - continued competitive pressures in the company's markets.
The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the
NU SKIN ENTERPRISES, INC. |
|||
Consolidated Statements of Income (Unaudited) |
|||
For the First Quarters Ended March 31, 2013 and 2012 |
|||
(in thousands, except per share amounts) |
|||
2013 |
2012 |
||
Revenue: |
|||
North Asia |
$ 188,193 |
$ 182,200 |
|
Greater China |
175,706 |
92,611 |
|
Americas |
76,541 |
66,340 |
|
South Asia/Pacific |
67,242 |
77,321 |
|
EMEA |
42,412 |
43,530 |
|
Total revenue |
550,094 |
462,002 |
|
Cost of sales |
90,045 |
75,756 |
|
Gross profit |
460,049 |
386,246 |
|
Operating expenses: |
|||
Selling expenses |
241,883 |
202,535 |
|
General and administrative expenses |
135,507 |
112,048 |
|
Total operating expenses |
377,390 |
314,583 |
|
Operating income |
82,659 |
71,663 |
|
Other income (expense), net |
112 |
3,635 |
|
Income before provision for income taxes |
82,771 |
75,298 |
|
Provision for income taxes |
28,489 |
27,469 |
|
Net income |
$ 54,282 |
$ 47,829 |
|
Net income per share: |
|||
Basic |
$ 0.93 |
$ 0.77 |
|
Diluted |
$ 0.90 |
$ 0.74 |
|
Weighted average common shares outstanding: |
|||
Basic |
58,352 |
62,230 |
|
Diluted |
60,566 |
65,017 |
NU SKIN ENTERPRISES, INC. |
|||
Consolidated Balance Sheets (Unaudited) |
|||
(in thousands) |
|||
March 31, 2013 |
December 31, 2012 |
||
ASSETS |
|||
Current assets: |
|||
Cash and cash equivalents |
$ 325,720 |
$ 320,025 |
|
Current investments |
8,534 |
13,378 |
|
Accounts receivable |
43,809 |
36,850 |
|
Inventories, net |
149,089 |
135,874 |
|
Prepaid expenses and other |
92,151 |
93,276 |
|
619,303 |
599,403 |
||
Property and equipment, net |
264,363 |
229,787 |
|
Goodwill |
112,446 |
112,446 |
|
Other intangible assets, net |
89,922 |
92,518 |
|
Other assets |
121,759 |
118,753 |
|
Total assets |
$ 1,207,793 |
$ 1,152,907 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||
Current liabilities: |
|||
Accounts payable |
$ 52,255 |
$ 47,882 |
|
Accrued expenses |
250,583 |
233,202 |
|
Current portion of long-term debt |
56,531 |
39,019 |
|
359,369 |
320,103 |
||
Long-term debt |
138,782 |
154,963 |
|
Other liabilities |
92,939 |
87,229 |
|
Total liabilities |
591,090 |
562,295 |
|
Stockholders' equity: |
|||
Class A common stock |
91 |
91 |
|
Additional paid-in capital |
319,802 |
317,293 |
|
Treasury stock, at cost |
(724,489) |
(714,853) |
|
Accumulated other comprehensive loss |
(55,372) |
(51,822) |
|
Retained earnings |
1,076,671 |
1,039,903 |
|
616,703 |
590,612 |
||
Total liabilities and stockholders' equity |
$ 1,207,793 |
$ 1,152,907 |
NU SKIN ENTERPRISES, INC. Actives/Sales Leaders Statistics |
||||||||||||||
As of March 31, 2013 |
As of March 31, 2012 |
% Increase (Decrease) |
||||||||||||
Actives |
Sales Leaders |
Actives |
Sales Leaders |
Actives |
Sales Leaders |
|||||||||
North Asia |
361,000 |
16,682 |
335,000 |
14,900 |
7.8% |
12.0% |
||||||||
Greater China |
261,000 |
22,011 |
151,000 |
11,551 |
72.8% |
90.6% |
||||||||
Americas |
163,000 |
6,273 |
170,000 |
5,776 |
(4.1%) |
8.6% |
||||||||
South Asia/Pacific |
98,000 |
5,337 |
91,000 |
4,911 |
7.7% |
8.7% |
||||||||
EMEA |
119,000 |
4,118 |
113,000 |
4,076 |
5.3% |
1.0% |
||||||||
Total |
1,002,000 |
54,421 |
860,000 |
41,214 |
16.5% |
32.0% |
||||||||
"Actives" are persons who purchased products directly from the company during the previous three months.
"Sales Leaders" include our independent distributors who have completed and who maintain specified sales requirements, and our sales employees and contractual sales promoters in
SOURCE
Investors, Scott Pond (801) 345-2657, spond@nuskin.com; Media, Kara Schneck (801) 345-2116, kschneck@nuskin.com